Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cerevel Therapeutics Holdings (CERE)
NASDAQ:CERE
RESEARCH TOOLSreports
Cerevel Therapeutics Holdings (CERE) Stock Price & Analysis
207 Followers
CERE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.59 - $43.59
Previous Close$41.99
Volume297.79K
Average Volume (3M)1.42M
Market Cap
$7.67B
Enterprise Value$7.00B
Total Cash (Recent Filing)$990.97M
Total Debt (Recent Filing)$368.61M
Price to Earnings (P/E)-15.7
Beta1.48
Next Earnings
May 13, 2024EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.67
Shares Outstanding181,576,482
10 Day Avg. Volume1,163,651
30 Day Avg. Volume1,420,667
Standard Deviation0.23
R-Squared0.12
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)11.32
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-16.10
Forecast
1Y Price Target
$45.00Price Target Upside6.76% Upside
Rating ConsensusHold
Number of Analyst Covering2
Cerevel Therapeutics Holdings News
PremiumCompany Announcements
Cerevel Therapeutics Advances in Merger Amid FTC Review
Bulls Say, Bears Say
Bulls Say
Company FinancialsABBV's recent $15bn bond sale to fund its acquisitions underscores a robust financial strategy, bolstering investor trust in the company's ability to successfully complete the CERE transaction.
Drug ApprovalCERE announced positive Phase 3 TEMPO-3 study data for tavapadon, a treatment for Parkinson's disease, meeting its primary endpoint and showing a significant increase in 'on' time without troublesome dyskinesia.
Mergers And AcquisitionsThe proposed acquisition of CERE by AbbVie is expected to enhance shareholder value as it progresses towards a mid-2024 closure, reflecting the strength and confidence in the strategic merger.
Bears Say
Acquisition ImpactThe proposed acquisition of CERE by AbbVie is likely to keep the stock price capped at the December 2023 acquisition offer price, leading to a Neutral rating on CERE.
Product Revenue ImpactTavapadon represents a relatively small revenue contributor to CERE's pipeline efforts.
Regulatory ChallengesThe FTC's Second Request for additional information on the CERE-ABBV merger extends the waiting period, potentially delaying the deal.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CERE FAQ
What was Cerevel Therapeutics Holdings’s price range in the past 12 months?
Cerevel Therapeutics Holdings lowest stock price was $19.59 and its highest was $43.59 in the past 12 months.
What is Cerevel Therapeutics Holdings’s market cap?
Currently, no data Available
When is Cerevel Therapeutics Holdings’s upcoming earnings report date?
Cerevel Therapeutics Holdings’s upcoming earnings report date is May 13, 2024 which is in 18 days.
How were Cerevel Therapeutics Holdings’s earnings last quarter?
Cerevel Therapeutics Holdings released its earnings results on Mar 20, 2024. The company reported -$0.766 earnings per share for the quarter, missing the consensus estimate of -$0.67 by -$0.096.
Is Cerevel Therapeutics Holdings overvalued?
According to Wall Street analysts Cerevel Therapeutics Holdings’s price is currently Undervalued.
Does Cerevel Therapeutics Holdings pay dividends?
Cerevel Therapeutics Holdings does not currently pay dividends.
What is Cerevel Therapeutics Holdings’s EPS estimate?
Cerevel Therapeutics Holdings’s EPS estimate is -$0.64.
How many shares outstanding does Cerevel Therapeutics Holdings have?
Cerevel Therapeutics Holdings has 181,576,480 shares outstanding.
What happened to Cerevel Therapeutics Holdings’s price movement after its last earnings report?
Cerevel Therapeutics Holdings reported an EPS of -$0.766 in its last earnings report, missing expectations of -$0.67. Following the earnings report the stock price went down -0.047%.
Which hedge fund is a major shareholder of Cerevel Therapeutics Holdings?
Among the largest hedge funds holding Cerevel Therapeutics Holdings’s share is Perceptive Advisors LLC. It holds Cerevel Therapeutics Holdings’s shares valued at 465M.
---
Cerevel Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$45.00 (6.76% Upside)
$45.00 (6.76% Upside)
Blogger Sentiment
Bullish
CERE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $89.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 12.8%
Last 30 Days ▼ 12.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.13%
12-Months-Change
Fundamentals
Return on Equity
-72.44%
Trailing 12-Months
Asset Growth
22.15%
Trailing 12-Months
Company Description
Cerevel Therapeutics Holdings
ARYA Sciences Acquisition Corp II is a blank check company.
---
CERE Company Deck
---
CERE Earnings Call
Q3 2023
0:00 / 0:00
---
CERE Stock 12 Months Forecast
Average Price Target
$45.00
▲(6.76% Upside)
Technical Analysis
Best Analysts Covering CERE
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+38.08%
reiterated a buy rating 6 months ago
Copying Matthew Harrison's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +38.08% per trade.
---